Abstract:Alzheimer's disease (AD) is a devastating disease characterized by synaptic and neuronal loss in the elderly. Compelling evidence suggests that soluble amyloid-β peptide (Aβ) oligomers induce synaptic loss in AD. Aβ-induced synaptic dysfunction is dependent on overstimulation of N-methyl-D-aspartate receptors (NMDARs) resulting in aberrant activation of redox-mediated events as well as elevation of cytoplasmic Ca2+, which in turn triggers downstream pathways involving phospho-tau (p-tau), caspases, Cdk5/dynamin-related protein 1 (Drp1), calcineurin/PP2B, PP2A, Gsk-3β, Fyn, cofilin, and CaMKII and causes endocytosis of AMPA receptors (AMPARs) as well as NMDARs. Dysfunction in these pathways leads to mitochondrial dysfunction, bioenergetic compromise and consequent synaptic dysfunction and loss, impaired long-term potentiation (LTP), and cognitive decline. Evidence also suggests that Aβ may, at least in part, mediate these events by causing an aberrant rise in extrasynaptic glutamate levels by inhibiting glutamate uptake or triggering glutamate release from glial cells. Consequent extrasynaptic NMDAR (eNMDAR) overstimulation then results in synaptic dysfunction via the aforementioned pathways. Consistent with this model of Aβ-induced synaptic loss, Aβ synaptic toxicity can be partially ameliorated by the NMDAR antagonists (such as memantine and NitroMemantine). PSD-95, an important scaffolding protein that regulates synaptic distribution and activity of both NMDA and AMPA receptors, is also functionally disrupted by Aβ. PSD-95 dysregulation is likely an important intermediate step in the pathological cascade of events caused by Aβ. In summary, Aβ-induced synaptic dysfunction is a complicated process involving multiple pathways, components and biological events, and their underlying mechanisms, albeit as yet incompletely understood, may offer hope for new therapeutic avenues.

Roles of O-GlcNAcylation on amyloid-β precursor protein processing, tau phosphorylation, and hippocampal synapses dysfunction in Alzheimer’s disease

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases

Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease

The alteration and role of glycoconjugates in Alzheimer's disease

Role of APP and Aβ in Synaptic Physiology.

The Role of MicroRNAs in Aβ Deposition and Tau Phosphorylation in Alzheimer’s Disease

O-GlcNAcylation and Its Roles in Neurodegenerative Diseases

Modifications and Trafficking of APP in the Pathogenesis of Alzheimer's Disease

Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease

Modifications and Trafficking of APP in the Pathogenesis of Alzheimer’s Disease

Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease

The Role of APP in Alzheimer’s Disease

Oligomeric Aβ-induced Synaptic Dysfunction in Alzheimer’s Disease

The role of ubiquitin proteasomal system and autophagy-lysosome pathway in Alzheimer’s disease

Discrepancy of synaptic and microtubular protein phosphorylation in the hippocampus of APP/PS1 and MAPT×P301S transgenic mice at the early stage of Alzheimer's disease

Molecular and cellular mechanisms for Alzheimer's disease: understanding APP metabolism.

Role of Cholinergic Signaling in Alzheimer’s Disease

Oxidative stress and the pathogenesis of Alzheimer's disease.

O-GlcNAcylation ameliorates the pathological manifestations of Alzheimer’s disease by inhibiting necroptosis

Autophagy in Alzheimer's Disease Pathogenesis: Therapeutic Potential and Future Perspectives.